Anika Net Receivables from 2010 to 2024

ANIK Stock  USD 17.20  0.23  1.36%   
Anika Therapeutics Net Receivables yearly trend continues to be quite stable with very little volatility. Net Receivables may rise above about 37.8 M this year. From the period between 2010 and 2024, Anika Therapeutics, Net Receivables regression line of its data series had standard deviation of  9,236,773 and standard deviation of  9,236,773. View All Fundamentals
 
Net Receivables  
First Reported
1993-06-30
Previous Quarter
33.8 M
Current Value
28.4 M
Quarterly Volatility
11.3 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Anika Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anika Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.9 M, Interest Expense of 1.3 M or Selling General Administrative of 103.5 M, as well as many indicators such as Price To Sales Ratio of 3.33, Dividend Yield of 0.0 or PTB Ratio of 1.73. Anika financial statements analysis is a perfect complement when working with Anika Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Latest Anika Therapeutics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Anika Therapeutics over the last few years. It is Anika Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anika Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Anika Net Receivables Regression Statistics

Arithmetic Mean23,612,013
Geometric Mean18,245,634
Coefficient Of Variation39.12
Mean Deviation6,457,462
Median23,079,000
Standard Deviation9,236,773
Sample Variance85.3T
Range37.5M
R-Value0.87
Mean Square Error22.9T
R-Squared0.75
Significance0.000029
Slope1,790,217
Total Sum of Squares1194.5T

Anika Net Receivables History

202437.8 M
202336 M
202234.6 M
202129.8 M
202024.1 M
201923.1 M
201820.8 M

About Anika Therapeutics Financial Statements

Anika Therapeutics investors utilize fundamental indicators, such as Net Receivables, to predict how Anika Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables36 M37.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(6.73)
Revenue Per Share
11.139
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.04)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.